By Donna Loyle, communications specialist, LIMR
Researchers seek to determine how well whole-brain radiation therapy works and compares it with or without hippocampal avoidance in patients diagnosed with small cell lung cancer (SCLC). Avoiding the hippocampus during whole-brain radiation could decrease the chance of side effects on memory and thinking.
Clinical trial NRG CC0033 is a randomized phase II/III study in which all participants receive prophylactic cranial irradiation (PCI), a technique used to combat the occurrence of metastasis to the brain in highly aggressive cancers that commonly metastasize to the brain, most notably SCLC.
Eligible participants are randomized to one of the following two treatment arms:
- Arm 1 (comparator): hippocampal avoidance PCI alone (25 Gy in 10 fractions)
- Arm 2 (experimental): PCI with hippocampal avoidance using intensity-modulated radiation therapy (25 Gy in 10 fractions)
After completion of study treatment, patients are followed every three months for one year, then every six months for three years, and then annually.
Albert DeNittis, MD, and Paul Gilman, MD, are the principal investigators for this study. For more, visit https://www.mainlinehealth.org/research/clinical-trials/nrg-cc003